Submissions from 2018
Externship Assessment Project: An Empirical Study of Supervisor Evaluations of Extern Work Performance, Margaret Reuter
It Takes a Village: Empowering the Dead Broke Parent, Wendy Tolson Ross
3D Printed Firearms and Brett Kavanaugh’s Misguided Approach to the Second Amendment, Allen Rostron
An Ill-Conceived Restriction on Gun Advertising, Allen Rostron
Why Do Gun-Makers Get Special Economic Protection?, Allen Rostron
Style, Substance, and the Right to Keep and Bear Assault Weapons, Allen K. Rostron
The Dickey Amendment on Federal Funding for Research on Gun Violence: A Legal Dissection, Allen K. Rostron
Prizes for Progress with a Caveat: DOE Offers $3 Million Incentive, Irma S. Russell
The Green Economy: A Marketplace of Ideas About Our Common Future, Irma S. Russell
The Green Economy: Strategic Planning for a Future?, Irma S. Russell
Juliana V. United States: Debating the Fundamentals of The Fundamental Right to a Sustainable Climate, Erin Ryan, Mary Wood, Jim Huffman, Irma S. Russell, and Richard Frank
Corporate Governance as Privately-Ordered Public Policy: A Proposal, Lynn A. Stout and Sergio Alberto Gramitto Ricci
Bias on Trial: Toward an Open Discussion of Racial Stereotypes in the Courtroom, Mikah K. Thompson
An American Tune: Refugee Children in U.S. Public Schools, Daniel B. Weddle
Update on FDA Regulation of mHealth and Wellness Devices, Barbara Zabawa
Submissions from 2017
The Power of the Public Defender Experience: Learning by Fighting for the Incarcerated and Poor, Patrick C. Brayer
What is Meant by Freedom?, Paul D. Callister
The Death of the Firm, June Carbone and Nancy Levit
Race, Rhetoric, and Judicial Opinions: Missouri as a Case Study, Brad Desnoyer and Anne Alexander
A Biotechnology-Centric Look at Fee Shifting in Patent Litigation Post-Octane Fitness, Christopher M. Holman
Caught Between a Rock and a Hard Place: How Limelight Compounds the Challenges Facing Biotechnology Innovators after Mayo and Myriad, Christopher M. Holman
Charting the Contours of Copyright Regime Optimized for Engineered Genetic Code, Christopher M. Holman
Eli Lilly v. Teva: Generic Companies Infringe under Akamai IV in Case of Divided Infringement, Christopher M. Holman
FDA’s Efforts to Tame the 'Wild West' of Regenerative Medicine, Christopher M. Holman
In Defense of Secondary Pharmaceutical Patents: Response to the UN's Guidelines for Pharmaceutical Patent Examination, Christopher M. Holman